A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy

A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable two (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Reduced threat Later age of onset No danger Dacomitinib web association No risk association No danger association Decreased danger of eR+ BC No risk association enhanced overall threat No threat association elevated threat of eR- BC increased risk elevated risk No threat association increased danger No danger association elevated danger No threat association increased danger No danger association improved risk No threat association Decreased danger No danger association increased general threat No threat association No danger association increased general danger No danger association Decreased danger of eR+ BC enhanced risk of eR- BC No risk association Decreased threat No risk association increased risk of eR+ No danger association No danger association Decreased risk of eR- BC Decreased threat of eR+ BC No risk association Decreased threat of eR+ No danger association No risk association elevated all round risk Decreased general danger No danger association No risk association elevated threat of eR- BC enhanced danger improved threat elevated threat elevated threat in eR+ earlier age of onset increased threat (A allele) earlier age of onset (C allele) Decreased risk Decreased danger elevated threat Decreased survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 CTX-0294885 web MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 three UTR HPGD three UTR IGF-1R three UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation enhanced frequency in BRCA1 carriers/no danger association elevated threat of TNBC Decreased threat improved danger and poor survival earlier age of onset enhanced risk enhanced danger Decreased danger Decreased general danger No danger association Decreased risk of eR+ BC No danger association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable two (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered danger Later age of onset No danger association No danger association No threat association Decreased threat of eR+ BC No risk association enhanced overall risk No risk association elevated danger of eR- BC improved risk increased risk No threat association elevated threat No risk association enhanced threat No risk association elevated risk No threat association enhanced threat No threat association Decreased threat No danger association elevated general risk No threat association No danger association improved all round threat No danger association Decreased risk of eR+ BC improved risk of eR- BC No threat association Decreased threat No threat association increased threat of eR+ No threat association No threat association Decreased risk of eR- BC Decreased threat of eR+ BC No threat association Decreased danger of eR+ No danger association No threat association elevated general threat Decreased general threat No danger association No danger association increased threat of eR- BC enhanced threat increased threat elevated threat elevated danger in eR+ earlier age of onset elevated danger (A allele) earlier age of onset (C allele) Decreased danger Decreased threat elevated danger Decreased survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B three UTR BRCA1 3 UTR HPGD three UTR IGF-1R three UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 three UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no risk association increased risk of TNBC Decreased threat improved threat and poor survival earlier age of onset elevated threat improved risk Decreased risk Decreased overall threat No danger association Decreased threat of eR+ BC No danger association increas.